1
|
Truong M, Tesfaye W, Sud K, Van C, Seth S, Croker N, Castelino RL. Drug-Related Problems and Sick Day Management Considerations for Medications that Contribute to the Risk of Acute Kidney Injury. J Clin Med 2024; 13:343. [PMID: 38256477 PMCID: PMC10816903 DOI: 10.3390/jcm13020343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 12/19/2023] [Accepted: 12/28/2023] [Indexed: 01/24/2024] Open
Abstract
BACKGROUND Medication use during acute illness increases the risk of experiencing drug related problems (DRPs), including acute kidney injuries. It is recommended that potentially nephrotoxic medications are withheld during acute illness, including sulfonylureas, angiotensin converting enzyme inhibitors, diuretics, metformin, angiotensin receptor blockers, non-steroidal anti-inflammatories and sodium glucose co-transporter 2 inhibitors (SADMANS). It is unknown if Australian pharmacists currently provide sick day medication management advice regarding SADMANS medications. Hence, we aimed to identify current DRPs and the recommendations made during residential medication management reviews (RMMRs), especially with SADMANS medications. METHODS A retrospective review of 408 RMMRs was conducted. DRPs and pharmacist recommendations were classified according to a modified DOCUMENT system. General practitioners' (GP) recommendations were also categorised. RESULTS Over 97% of residents experienced at least one DRP. Common problems for non-SADMANS medications were "toxicity or adverse drug reaction", "drug selection" and "over/underdosing" and those for SADMANS medications included "toxicity or adverse drug reaction", "monitoring" and "drug selection". GPs agreed with pharmacist recommendations approximately 40% of the time. No pharmacists provided sick day medication management advice for SADMANS medications. CONCLUSION DRPs remain highly prevalent in aged care facilities. Medication reviews effectively identify and resolve DRPs approximately 40% of the time, but do not currently minimise the risk associated with using SADMANS medications during sick days, which is a potential area of improvement.
Collapse
Affiliation(s)
- Mimi Truong
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney 2006, Australia; (W.T.); (C.V.); (R.L.C.)
| | - Wubshet Tesfaye
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney 2006, Australia; (W.T.); (C.V.); (R.L.C.)
| | - Kamal Sud
- Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney 2006, Australia
- Nepean Kidney Research Centre, Department of Renal Medicine, Nepean Hospital, Nepean and Blue Mountains Local Health District, Kingswood 2747, Australia
| | - Connie Van
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney 2006, Australia; (W.T.); (C.V.); (R.L.C.)
| | - Shrey Seth
- Manipal Academy of Higher Education (MAHE), The University of Sydney, Sydney 2006, Australia
| | | | - Ronald Lynel Castelino
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney 2006, Australia; (W.T.); (C.V.); (R.L.C.)
- Pharmacy Department, Blacktown Hospital, WSLHD, Blacktown 2148, Australia
| |
Collapse
|
2
|
Niino C, Tholemeier L, Meyer R, Siedhoff M, Wright K, Truong M. Telemedicine improves visit efficiency in minimally invasive gynecologic surgery practice. Am J Obstet Gynecol 2023. [DOI: 10.1016/j.ajog.2022.12.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/10/2023]
|
3
|
Hamilton K, Konate N, Meyer R, Jasmine G, Wright K, Siedhoff M, Scheib S, Truong M. Racial and gender representation trends among national obstetrics and gynecology society leadership. Am J Obstet Gynecol 2023. [DOI: 10.1016/j.ajog.2022.12.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
|
4
|
Kittleson M, Patel J, Chang D, Patel N, Singer-Englar T, Sindha I, Truong M, Hage A, Ramzy D, Czer L, Kobashigawa J. Sex Disparities in Heart Transplant Waitlist Status After the Donor Heart Allocation Policy Change. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Chang D, Kittleson M, Patel J, Kransdorf E, Singer-Englar T, Patel N, Truong M, Nikolova A, Trento A, Czer L, Kobashigawa J. Do Women Truly Have Less Than Optimal Outcome Post-Heart Transplantation Compared to Men. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Molina A, Truong M. 33 Docking the robot in 10 steps. Am J Obstet Gynecol 2021. [DOI: 10.1016/j.ajog.2021.04.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Choi B, Lee J, Truong M, Kim H, Yang S, Min B. Regeneration of cartilage defect using an artificial engineered cartilage with an injectable property. Cytotherapy 2020. [DOI: 10.1016/j.jcyt.2020.03.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Bradley S, Truong M, Suarez-Quian C, Alam P, Sokol A. An Optimal Cadaveric Model for Laparoscopic Gynecologic Surgical Training. J Minim Invasive Gynecol 2018. [DOI: 10.1016/j.jmig.2018.09.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Ely L, Truong M, Advincula A. Surgical Management of Adenomyoma with Uterine Wall Dissection Post-Myomectomy: A Case Report. J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Madueke-Laveaux O, Advincula A, Landau-Cahana R, Walters R, Grimes C, Kim J, Simpson K, Truong M, Young C, Ryntz T. A Comparison of Carbon Dioxide (CO 2 ) Absorption Rates in Gynecologic Laparoscopy with a Valveless Insufflation System Versus Standard Insufflation System at Intra-Abdominal Pressures of 10 mmHg and 15 mmHg – A Randomized Controlled Trial. J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Abstract
Background Constipation is a common condition in children. Little is known about the acute health care utilization of constipated children, including how many present to the paediatric emergency department (ED), the spectrum of presenting complaints, investigations and treatments used. Methods We conducted a cross-sectional chart review of all 42,875 visits to British Columbia Children's Hospital ED between August 31, 2012 and September 1, 2013. All visits were assessed for a potential diagnosis of constipation and a total of 913 patients were included. We recorded the chief complaints, tests performed and therapies administered in the ED and measures of flow/efficiency including waiting time (WT), length of stay (LOS) and disposition. Results Constipation-related visits comprised 2.1% of overall visits. Abdominal pain was found to be the most common presenting complaint in 65.6% of patients; however, 11.9% of patients presented with complaints unrelated to the gastrointestinal tract. Abdominal radiographs were obtained in nearly one-third of patients and almost half of the patients received a fleet enema in the ED. Only a quarter of patients were discharged home on longer-term management. Measures of ED flow were similar between groups, with no meaningful difference in WT or LOS. The vast majority of children (99.7%) were discharged home. Conclusions Constipation can be treated as an out-patient, rather than burdening the paediatric ED unnecessarily. This study demonstrates over utilization of radiologic tests and invasive ED treatments and an under utilization of outpatient medication and dietary counselling that may contribute to unnecessary return ED visits.
Collapse
Affiliation(s)
- Alison Nutter
- Department of Pediatrics, BC Children's Hospital, Vancouver, British Columbia
| | - Garth Meckler
- Department of Pediatrics, BC Children's Hospital, Vancouver, British Columbia
| | - Mimi Truong
- Department of Pediatrics, BC Children's Hospital, Vancouver, British Columbia
| | - Quynh Doan
- Department of Pediatrics, BC Children's Hospital, Vancouver, British Columbia
| |
Collapse
|
12
|
Truong M, Meckler G, Doan QH. Emergency Department Return Visits Within a Large Geographic Area. J Emerg Med 2017; 52:801-808. [PMID: 28228344 DOI: 10.1016/j.jemermed.2017.01.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Revised: 12/30/2016] [Accepted: 01/04/2017] [Indexed: 10/20/2022]
Abstract
BACKGROUND Return visits to the emergency department (RTED) contribute to overcrowding and may be a quality of care indicator. Previous studies focused on factors predicting returns to and from the same center. Little is known about RTEDs across a range of community and specialty hospitals within a large geographic area. OBJECTIVE We sought to measure the frequency of pediatric RTEDs and describe their directional pattern across centers in a large catchment area. METHODS We conducted a multicenter, retrospective cross-sectional study of pediatric emergency visits in the Vancouver lower mainland within 1 year. Visits were linked across study sites, including one pediatric quaternary care referral center and 17 sites ranging from large regional centers to smaller community emergency departments (EDs). Returns were defined as subsequent visits to any site with a compatible diagnosis within 7 days of an index visit. RESULTS Among a total of 139,278 index ED visits by children, 12,133 (8.7% [95% confidence interval 8.6-8.9%]) were associated with 14,645 return visits to an ED. Three quarters of all index visits occurred at a general ED center, of which 8.9% had at least one RTED and 22% of these returns occurred at the pediatric ED (PED). Among PED index visits, 8.2% had at least one RTED and 13.6% of these returned to a general center. Overall, 38.9% of all RTEDs occurred at the PED. Multivariate regression did not identify any statistically significant association between ED crowding measures and likelihood of RTEDs. CONCLUSIONS Compared to single-center studies, this study linking hospitals within a large geographic area identified a higher proportion of RTEDs with a disproportionate burden on the PED.
Collapse
Affiliation(s)
- Mimi Truong
- Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Garth Meckler
- Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Division of Emergency Medicine, British Columbia Children's Hospital, Vancouver, British Columbia, Canada
| | - Quynh H Doan
- Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Division of Emergency Medicine, British Columbia Children's Hospital, Vancouver, British Columbia, Canada
| |
Collapse
|
13
|
Truong M, Tobias C, Ratan R. A Prospective Trial: Traditional versus Video-Based Teaching for Minimally Invasive Gynecologic Surgery. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Mattingly P, Tanaka A, Julian D, Truong M, Simpson K, Madueke-Laveaux S, Smith R. Virtual Reality Robotic Simulation Performance Assessment: Simulator Metrics vs. GEARS. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Blute ML, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol 2016; 35:729-735. [PMID: 27631325 DOI: 10.1007/s00345-016-1933-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 09/06/2016] [Indexed: 12/31/2022] Open
Abstract
INTRODUCTION A significant proportion of patients that fail active surveillance (AS) for prostate cancer management do so because of cancer upgrading. A previously validated upgrading nomogram generates a score that predicts risk of biopsy Gleason 6 upgrading following radical prostatectomy in lower-risk populations that are candidates for Active Surveillance (Cancer, 2013). OBJECTIVES We hypothesize that the upgrading risk (UR) score generated by this nomogram at diagnosis improves the ability to predict patients that will subsequently fail AS. METHODS To evaluate the nomogram, retrospective data from several institutional cohorts of patients who met AS criteria, group 1 (n = 75) and group 2 (n = 1230), were independently examined. A UR score was generated using the coefficients from the nomogram consisting of PSA density (PSAD), BMI, maximum % core involvement (MCI), and number of positive cores. AS failure was defined as Gleason score (GS) >6, >50 % maximum core involvement, or >2 positive cores on biopsy. Univariate and multivariate Cox proportional-hazards regression models, upgrading risk score, and other clinicopathologic features were each assessed for their ability to predict AS failure. RESULTS Clinicopathologic parameters were similar in both groups with the exception of mean PSAD (0.13 vs. 0.11, p < 0.01) and follow-up (2.1 vs. 3.2 years, p = 0.2). Most common cause of AS failure was GS > 6 (group 1) compared to >2 positive cores (group 2). On univariate analysis in both populations, features at diagnosis including PSAD and the UR score were significant in predicting AS failure by upgrading (Gleason > 6) and any failure. Multivariate analysis revealed the UR score predicts AS failure by GS upgrading (HR 1.8, 95 % CI 1.12-2.93; p = 0.01) and any failure criteria (HR 1.7, 95 % CI 1.06-2.65); p = 0.02) for group 1. Likewise, the UR score in group 2 predicts AS failure with GS upgrading (HR 1.3, 95 % CI 1.15-1.42; p < 0.0001) and any failure criteria (HR 1.18, 95 % CI 1.18-1.38; p < 0.0001). An ROC generated an AUC of 0.66. Decision curve analysis demonstrated a high net benefit for the UR score across a range of threshold probabilities. Based on these outcomes, at 3 years, patients in the lowest risk quartile have a 15 % risk of AS failure versus a 46 % risk in the highest quartile (p < 0.0001). CONCLUSIONS The UR score was predictive of pathologic AS failure on multivariate analysis in several AS cohorts. It outperformed single clinicopathologic criteria and may provide a useful adjunct using clinicopathologic data to stratify patients considering AS.
Collapse
Affiliation(s)
- M L Blute
- Department of Urology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Madison, WI, 53705, USA.,University of Wisconsin Carbone Comprehensive Cancer Center, 1111 Highland Ave, Madison, WI, 53705, USA
| | - J M Shiau
- Department of Urology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Madison, WI, 53705, USA
| | - M Truong
- Department of Urology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Madison, WI, 53705, USA.,Department of Urology, University of Rochester School of Medicine, 601 Elmwood Ave, Rochester, NY, 14642, USA
| | - Fangfang Shi
- Department of Urology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Madison, WI, 53705, USA
| | - E J Abel
- Department of Urology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Madison, WI, 53705, USA.,University of Wisconsin Carbone Comprehensive Cancer Center, 1111 Highland Ave, Madison, WI, 53705, USA
| | - T M Downs
- Department of Urology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Madison, WI, 53705, USA.,University of Wisconsin Carbone Comprehensive Cancer Center, 1111 Highland Ave, Madison, WI, 53705, USA
| | - D F Jarrard
- Department of Urology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Madison, WI, 53705, USA. .,University of Wisconsin Carbone Comprehensive Cancer Center, 1111 Highland Ave, Madison, WI, 53705, USA. .,Environmental and Molecular Toxicology, University of Wisconsin, 1400 University Ave, Madison, WI, 53706, USA.
| |
Collapse
|
16
|
DiNapoli M, Truong M, Kostolias A, Johnson D, Kearney J, Burke W. Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter? J Minim Invasive Gynecol 2015; 22:S58-S59. [DOI: 10.1016/j.jmig.2015.08.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Simpson KM, Perez M, Tanaka A, Truong M, Smith RD. GEARS – An Objective Tool to Differentiate Robotic Surgical Skill and Experience. J Minim Invasive Gynecol 2015; 22:S10. [DOI: 10.1016/j.jmig.2015.08.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Simpson K, Tanaka A, Graddy C, Perez M, Truong M, Smith R. Video Game Impact on Basic Robotic Surgical Skills. J Minim Invasive Gynecol 2015; 22:S156-S157. [DOI: 10.1016/j.jmig.2015.08.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Truong M, Tanaka A, Simpson K, Advincula A, Smith R. A Prospective Randomized Controlled Comparative Study on Surgical Training Methods and Impact on Surgical Performance: Virtual Reality Robotic Simulation vs Didactic Lectures. J Minim Invasive Gynecol 2014. [DOI: 10.1016/j.jmig.2014.08.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Truong M, Halfon J. Interstitial Ectopic Pregnancy: An Overview and Example of Laparoscopic Management. J Minim Invasive Gynecol 2014. [DOI: 10.1016/j.jmig.2014.08.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Shah B, Qureshi M, Jalisi S, Grillone G, Salama A, Cooley T, Zaner K, Sakai O, Truong M. Analysis of Decision Making at a Multidisciplinary Head and Neck Tumor Board Incorporating Evidence-Based NCCN Guidelines. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1779] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Shin J, Truong M. Racial Disparities in Laryngeal Cancer Treatment and Outcome in the United States: A Population-Based SEER Analysis of 24,069 Patients. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Russo A, Truong M, Busse P, Adams J, Deschler D, Lin D, Wirth L, John C, Chan A. Long-term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Truong M, Logue J, Qureshi M, Zaner K, Cooley T, Jalisi S. Comparing Acute Toxicity Outcome of Chemoradiation therapy Regimens in Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1271] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Truong M, O'Sullivan B, Huang S. Comparing Clinical Presentations of HPV-positive and HPV-negative Oropharyngeal Carcinomas. J Med Imaging Radiat Sci 2013. [DOI: 10.1016/j.jmir.2013.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
26
|
Dau A, Komal P, Truong M, Morris G, Evans G, Nashmi R. RIC-3 differentially modulates α4β2 and α7 nicotinic receptor assembly, expression, and nicotine-induced receptor upregulation. BMC Neurosci 2013; 14:47. [PMID: 23586521 PMCID: PMC3637639 DOI: 10.1186/1471-2202-14-47] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Accepted: 04/03/2013] [Indexed: 12/04/2022] Open
Abstract
Background Recent work has shown that the chaperone resistant to inhibitors of acetylcholinesterase (RIC-3) is critical for the folding, maturation and functional expression of a variety of neuronal nicotinic acetylcholine receptors. α7 nicotinic receptors can only assemble and functionally express in select lines of cells, provided that RIC-3 is present. In contrast, α4β2 nicotinic receptors can functionally express in many cell lines even without the presence of RIC-3. Depending on the cell line, RIC-3 has differential effects on α4β2 receptor function – enhancement in mammalian cells but inhibition in Xenopus oocytes. Other differences between the two receptor types include nicotine-induced upregulation. When expressed in cell lines, α4β2 receptors readily and robustly upregulate with chronic nicotine exposure. However, α7 nicotinic receptors appear more resistant and require higher concentrations of nicotine to induce upregulation. Could the coexpression of RIC-3 modulate the extent of nicotine-induced upregulation not only for α7 receptors but also α4β2 receptors? We compared and contrasted the effects of RIC-3 on assembly, trafficking, protein expression and nicotine-induced upregulation on both α7 and α4β2 receptors using fluorescent protein tagged nicotinic receptors and Förster resonance energy transfer (FRET) microscopy imaging. Results RIC-3 increases assembly and cell surface trafficking of α7 receptors but does not alter α7 protein expression in transfected HEK293T cells. In contrast, RIC-3 does not affect assembly of α4β2 receptors but increases α4 and β2 subunit protein expression. Acute nicotine (30 min exposure) was sufficient to upregulate FRET between α4 and β2 subunits. Surprisingly, when RIC-3 was coexpressed with α4β2 receptors nicotine-induced upregulation was prevented. α7 receptors did not upregulate with acute nicotine in the presence or absence of RIC-3. Conclusions These results provide interesting novel data that RIC-3 differentially regulates assembly and expression of different nicotinic receptor subunits. These results also show that nicotine-mediated upregulation of α4β2 receptors can be dynamically regulated by the presence of the chaperone, RIC-3. This could explain a novel mechanism why high affinity α4β2 receptors are upregulated in specific neuronal subtypes in the brain and not others.
Collapse
|
27
|
Chan A, Adams J, Weyman E, Parambi R, Goldsmith T, Holman A, Truong M, Busse P, Delaney T. A Phase II Trial of Proton Radiation Therapy With Chemotherapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.391] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Qureshi M, Romesser P, Ajani A, Kachnic L, Truong M. Gross Tumor Volume Presentation in Different Race/Ethnic Groups as a Determinant of Treatment Outcome in Head-and-Neck Cancer Patients Treated With Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Romesser P, Shah B, Qureshi M, Jalisi S, Subramaniam R, Truong M. Prognostic Utility of Pretreatment Metabolic Tumor Volume, Gross Tumor Volume, Maximum Standardized Uptake Value in Head-and-Neck Cancer Patients Receiving IMRT. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Zhang J, Qureshi M, Kovalchuk N, Truong M. Correlating Planned Radiation Dose to the Cochlea With Primary Site and Tumor Stage in Head-and-Neck Patients Treated With Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Romesser P, Qureshi M, Kovalchuk N, Orlina L, Willins J, Truong M. Correlation of Brachial Plexus Dose With Gross Tumor Volume in Head and Neck IMRT. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Truong M, Romesser P, Qureshi M, Orlina L, Willins J. Dose Volume Histogram Analysis of Routine Brachial Plexus Contouring for Head and Neck Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.826] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Hawksworth S, Qureshi M, XIang H, Truong M, Chin L, Holsapple J, Willins J, Kachnic L, Russo G. Ray-Trace is Inferior to Monte Carlo Dose Calculation Algorithm for Intracranial Robotic Radiosurgical Treatment: A Comparative Dosimetry Study. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Romesser P, Qureshi M, Kachnic L, Truong M. Non-English Speaking Language Rather than Non-white Race Predicts Treatment Outcomes in Patients Treated with Radiotherapy (RT) for Head and Neck Cancer (HNC). Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.878] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
35
|
Romesser P, Qureshi M, Chatburn L, Subramaniam R, Truong M. Superior Prognostic Utility of Gross Tumor Volume Compared to Standardized Uptake Value using PET/CT in Head and Neck Cancer Patients Treated with Radiotherapy. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Truong M, Damato A, Qureshi M, Hirsch A, Vassilakis N, Schuller B, Russo G, Willins J, Kachnic L. The Effect of Time from Surgery on Lumpectomy Cavity Variations before and during Breast Radiotherapy. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Russo G, Qureshi M, Truong M, Hirsch A, Orlina L, Bohrs H, Clancy P, Willins J, Kachnic L. Daily Orthogonal Kilovoltage Imaging using Gantry Mounted on Board Imaging Results in a Reduction in Treatment Delivery Deviations. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Wang J, Truong M, Adams J, Cianchetti M, Liebsch N, Busse P, McIntyre J, Chan A. A Comparison of Definitive with Postoperative Proton Beam Therapy for Locally Advanced Sinonasal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
39
|
Subramaniam RM, Truong M, Peller P, Sakai O, Mercier G. Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. AJNR Am J Neuroradiol 2009; 31:598-604. [PMID: 19910448 DOI: 10.3174/ajnr.a1760] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The hybrid technique of PET/CT has significantly impacted the imaging and management of HNSCC since its introduction in 2001 and has become the technique of choice for imaging of this cancer. Diagnostic FDG-PET/CT is useful for identification of an unknown primary tumor, delineation of extent of primary tumor, detection of regional lymph node involvement even in a normal-sized node, detection of distant metastases and occasional synchronous primary tumor, assessment of therapy response, and long-term surveillance for recurrence and metastases. The role of PET/CT is evolving in radiation therapy planning. Combined diagnostic PET/CT provides the best anatomic and metabolic in vivo information for the comprehensive management of HNSCC.
Collapse
Affiliation(s)
- R M Subramaniam
- Department of Radiology, Boston Medical Center and Boston University, Massachusetts 02118, USA.
| | | | | | | | | |
Collapse
|
40
|
Saito N, Sakai O, Lee R, Wang J, Truong M. Assessing CT Perfusion Changes of Salivary Glands during Head and Neck Radiotherapy. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Wear C, Wang J, Truong M, Liebsch N, Busse P, Clark J, Chan A. Preliminary Results of a Phase II Trial with Proton Beam Therapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
42
|
Truong M, Lee R, Saito N, Wang J, Ozonoff A, Sullivan J, Sakai O. Predicting Radiation Response in Head and Neck Cancer using Serial CT Perfusion Imaging during Radiotherapy. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.909] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
43
|
|
44
|
Kim ES, Kies MS, Glisson BS, Tsao A, Ginsberg LE, Holsinger FC, Burke BJ, Truong M, Papadimitrakopoulou VA, Lippman SM. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6013] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6013 Background: Interrupting the epidermal growth factor receptor (EGFR) signaling pathway has shown promise in a variety of cancers and preclinical data has demonstrated possible synergy with platinums and taxanes. Treatment options for recurrent/metastatic HNSCC are limited. A study of cisplatin and docetaxel showed a response rate of 40% and 9.6 month median survival. Erlotinib, an EGFR tyrosine kinase inhibitor, had a 4.3% response rate as single agent in HNSCC. Because of the possible synergy and efficacy, we proposed to study the combination of cisplatin, docetaxel and erlotinib in advanced HNSCC. Methods: Patients (pts) were required to have adequate performance status, measurable disease, no prior EGFR therapy, and may have received prior induction, concomitant or adjuvant chemotherapy, but not for recurrent/metastatic disease. Sites of disease included squamous cell head and neck sites excluding nasopharynx and sinus. Treatment included docetaxel 75 mg/m2 and cisplatin 75 mg/m2 intravenously every 3 weeks and erlotinib 150 mg by mouth daily. All agents were started on day 1. Pts were treated with growth factor support. Results: The trial has completed accrual to 50 pts. 47 pts are available for analysis at this time. Median age is 56 years (range 39–72). ECOG PS is 0, 1, 2 (6, 29, 2 pts). 43 pts are evaluable for efficacy. All responses were confirmed via RECIST. Complete responses have been in observed in 4 pts, partial responses in 25 pts and 12 pts have stable disease for an overall response rate of 67% and disease control rate of 95%. After a follow-up of 19 months, median overall survival was 11 months (8.61, 22.5, 95% CI) and progression free survival was 6.01 months (4.37, 8.25). 6 pts had grade 3/4 febrile neutropenia, 4 pts had grade 3/4 dehydration, 3 pts had grade 3 diarrhea, and 2 pts had grade 3/4 GI bleeding. The most common grade 1–2 toxicities were diarrhea, nausea, and rash. Conclusions: The combination of cisplatin, docetaxel and erlotinib is well tolerated and has very encouraging activity in recurrent/metastatic HNSCC. Tissues are being collected and analyzed for correlative markers including downstream EGFR pathway markers (p-akt, mek, k-ras). Final efficacy and biomarker results will be presented at the annual meeting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. S. Kim
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - M. S. Kies
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - B. S. Glisson
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - A. Tsao
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - L. E. Ginsberg
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - F. C. Holsinger
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - B. J. Burke
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - M. Truong
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - S. M. Lippman
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
45
|
Lu C, Lee JJ, Komaki R, Herbst RS, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong M, Fisch MJ. A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7527] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7527 Background: Æ-941 is a shark cartilage extract with antiangiogenic properties. We conducted a placebo-controlled trial testing Æ-941, with IC and CRT, in unresectable stage III NSCLC. Methods: Eligibility criteria included performance status (PS) < 2, weight loss < 10%. Subjects received one of two treatment regimens depending on site of enrollment: carboplatin (C) (AUC 6) and paclitaxel (P) (200 mg/m2) × 2 cycles followed by CRT (60 Gy/30 fractions) with weekly C (AUC 2) and P (45 mg/m2) × 6 doses or cisplatin (CDDP) (75 mg/m2, d1) and vinorelbine (V) (30 mg/m2, d1 and 8) × 2 cycles followed by CRT (60 Gy/30 fractions) with CDDP (75 mg/m2, day 1) and V (15 mg/m2, d1 and 8) × 2 cycles. Subjects were randomized to receive Æ-941 (Arm A) or placebo (Arm B), 120 mL orally twice daily, at the start of IC and continuing after CRT as maintenance therapy. Randomization was stratified for stage, gender, and type of chemotherapy. The primary endpoint was overall survival (OS), with a planned sample size of 756 subjects providing 80% power to detect a 25% difference in OS, assuming a control arm median survival time (MST) of 13 months, type I error 0.05. Results: Between 6/00 and 2/06, 384 subjects were enrolled onto the trial and randomized. In 2/06 the trial was closed to new patient entry due to insufficient accrual. This final analysis is based on 379 randomized and eligible subjects (188 arm A, 191 arm B). Subject characteristics: 60% male, median age 63 years (range 37–84), 56% stage IIIB, 58% C-based chemotherapy, median follow-up 3.7 years. There was no significant difference in OS between arms A and B, with MSTs of 14.4 (95% CI 12.6–17.9) and 15.6 (95% CI 13.8–18.1) months, respectively (log-rank p=0.73). OS by pre-specified stratification factors: stage IIIB vs IIIA (MST 13.9 vs. 17.4 months, p=0.25), C vs. CDDP chemotherapy (MST 14.4 vs. 16.7 months, p=0.13), and male vs. female (MST 15.7 vs. 15.1 months, p=0.74). The study drug was well tolerated. Fewer subjects in arm A experienced grade 3 or higher adverse events (66% vs. 77%, p=0.018). Conclusions: The addition of Æ−941 to IC and CRT does not improve OS in patients with unresectable stage III NSCLC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Lu
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - J. J. Lee
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - R. Komaki
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - R. S. Herbst
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - W. K. Evans
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - H. Choy
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - P. Desjardins
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - B. T. Esparaz
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - M. Truong
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| | - M. J. Fisch
- UT MD Anderson Cancer Center, Houston, TX; Juravinski Cancer Centre, Hamilton, ON, Canada; UT Southwestern Medical Center, Dallas, TX; Hopital Charles Lemoyne, Greenfield Park, PQ, Canada; Central Illinois CCOP, Decatur, IL
| |
Collapse
|
46
|
Kim ES, Kies MS, Glisson BS, Ginsberg LE, Holsinger FC, Burke BJ, Truong M, Tsao AS, Hong WK, Lippman SM. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5521] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5521 Background: Interrupting the epidermal growth factor receptor (EGFR) signaling pathway has shown promise in a variety of cancers and preclinical data has demonstrated possible synergy with platinums and taxanes. Treatment options for advanced or recurrent HNSCC are limited. A study of cisplatin and docetaxel showed a response rate of 40% and 9.6 month median survival. Erlotinib, an EGFR tyrosine kinase inhibitor, had a 4.3% response rate in HNSCC. Because of the possible synergy and efficacy, we proposed to study the combination of cisplatin, docetaxel and erlotinib in advanced HNSCC. Methods: Patients (pts) were required to have adequate performance status, measurable disease, no prior EGFR therapy, and may have received one regimen of induction, concomitant or adjuvant chemotherapy, but not for recurrent/metastatic disease. Sites of disease included squamous cell head and neck sites excluding nasopharynx and sinus. Treatment included docetaxel 75mg/m2 and cisplatin 75mg/m2, intravenously every 3 weeks and erlotinib 150 mg by mouth daily. Patients were treated with growth factor support. Results: 37 pts have been enrolled thus far. Median age is 56 years (range 39–72). Median ECOG PS is 1 (range 0–2). 32 pts are evaluable for confirmed response using RECIST criteria. Complete responses have been in observed in 3 pts, partial responses in 18 pts and 8 pts have stable disease for an overall response rate of 66% and disease control rate of 91%. Only 2 pts progressed after 2 cycles of treatment. 5 pts had grade 3/4 neutropenia (2 febrile),1 pt had grade 4 diarrhea, and 2 pts had grade 3 rash. The most common grade 1–2 toxicities were diarrhea, nausea, and rash. Conclusion: The combination of cisplatin, docetaxel and erlotinib is well tolerated and has very encouraging activity in advanced HNSCC. Data collection for response rate, duration of response and survival is ongoing. Trial accrual continues up to 50 patients and biopsies are being collected for correlative markers including downstream EGFR pathway markers (p-akt, mek, k-ras). The full data set will be presented at the annual meeting. [Table: see text]
Collapse
Affiliation(s)
- E. S. Kim
- M. D. Anderson Cancer Center, Houston, TX
| | - M. S. Kies
- M. D. Anderson Cancer Center, Houston, TX
| | | | | | | | | | - M. Truong
- M. D. Anderson Cancer Center, Houston, TX
| | - A. S. Tsao
- M. D. Anderson Cancer Center, Houston, TX
| | - W. K. Hong
- M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
47
|
Lu C, Komaki R, Herbst RS, Evans WK, Lee JJ, Truong M, Moore CA, Choy H, Bleyer A, Fisch MJ. A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7144] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Lu
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - R. Komaki
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - R. S. Herbst
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - W. K. Evans
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - J. J. Lee
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - M. Truong
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - C. A. Moore
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - H. Choy
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - A. Bleyer
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| | - M. J. Fisch
- M.D. Anderson Cancer Ctr, Houston, TX; Juravinski Cancer Ctr, Hamilton, ON, Canada; Univ of Texas Southwestern Medcl Ctr, Dallas, TX
| |
Collapse
|
48
|
Formenti S, Truong M, Goldberg J, Rosenstein B, DeWeyngaert K. Phase I-II study of prone accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2004. [DOI: 10.1016/j.ijrobp.2004.07.269] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
49
|
Lu C, Zhao H, Truong M, Dong Q, Spitz MR, Wu X. Association between glutathione S-transferase (GST) P1 polymorphisms and survival of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Lu
- M. D. Anderson Cancer Center, Houston, TX
| | - H. Zhao
- M. D. Anderson Cancer Center, Houston, TX
| | - M. Truong
- M. D. Anderson Cancer Center, Houston, TX
| | - Q. Dong
- M. D. Anderson Cancer Center, Houston, TX
| | | | - X. Wu
- M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
50
|
Sandler AB, Blumenschein GR, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson DH, Herbst RS. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2000] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. B. Sandler
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - G. R. Blumenschein
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - T. Henderson
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - J. Lee
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - M. Truong
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - E. Kim
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - B. Mass
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - B. Garcia
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - D. H. Johnson
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| | - R. S. Herbst
- Vanderbilt-Ingram Cancer Center, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Genentech, San Francisco, CA
| |
Collapse
|